This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Transcept Pharmaceuticals, Inc. Adopts Tax Benefit Preservation Plan

As part of the plan, the Transcept Board of Directors declared a dividend of one preferred stock purchase right, which are referred to as "rights," for each outstanding share of Transcept common stock.  The dividend will be payable to holders of record as of the close of business on September 27, 2013. Any shares of Transcept common stock issued after the record date will be issued together with the rights.

The rights will be exercisable if a person or group, without the approval of the Transcept Board, acquires, or obtains the right to acquire, beneficial ownership of 4.99 percent or more of the Transcept common stock. The rights also will be exercisable if a person or group that already beneficially owns 4.99 percent or more of the Transcept common stock, without Board approval, acquires additional shares (other than as a result of a dividend or a stock split). Existing Transcept stockholders that, as of September 13, 2013, beneficially own in excess of 4.99 percent of the common stock will be "grandfathered in" at their current ownership level.  If the rights become exercisable, all holders of rights, other than the person or group triggering the rights, will be entitled to purchase Transcept common stock at a 50 percent discount. Rights held by the person or group triggering the rights will become void and will not be exercisable. 

Beneficial ownership of shares is calculated under the plan in accordance with the applicable rules of Section 382 of the Internal Revenue Code. The calculations are complex, and stockholders should contact Transcept if they have any questions regarding their ownership, the 4.99 percent trigger amount or any other matters related to the plan.

The Board of Directors has established procedures by which it will consider requests by stockholders to exempt certain acquisitions of Transcept common stock from the plan if the Board determines that doing so would not limit or impair the availability of the tax benefits or is otherwise in the best interests of Transcept.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs